Seven Fleet Capital Management LP Invests $10.65 Million in Century Therapeutics, Inc. $IPSC

Seven Fleet Capital Management LP acquired a new stake in shares of Century Therapeutics, Inc. (NASDAQ:IPSC) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 4,347,826 shares of the company’s stock, valued at approximately $10,652,174. Century Therapeutics makes up 0.0% of Seven Fleet Capital Management LP’s portfolio, making the stock its 11th biggest position. Seven Fleet Capital Management LP owned approximately 2.41% of Century Therapeutics at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in IPSC. Quadrant Private Wealth Management LLC increased its position in shares of Century Therapeutics by 31.0% during the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after acquiring an additional 4,736 shares in the last quarter. Geode Capital Management LLC lifted its stake in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 456,115 shares of the company’s stock worth $454,000 after acquiring an additional 10,806 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Century Therapeutics during the 1st quarter worth $29,000. State of Wyoming acquired a new stake in Century Therapeutics during the 2nd quarter valued at $82,000. Finally, Bank of America Corp DE boosted its stake in shares of Century Therapeutics by 109.1% in the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after purchasing an additional 34,466 shares during the period. 50.20% of the stock is owned by institutional investors.

Century Therapeutics Stock Down 9.0%

Shares of IPSC traded down $0.20 during midday trading on Friday, reaching $2.03. 629,320 shares of the stock were exchanged, compared to its average volume of 1,370,229. The firm has a 50 day simple moving average of $2.17 and a 200-day simple moving average of $2.22. The company has a market cap of $367.58 million, a price-to-earnings ratio of -2.18 and a beta of 1.57. Century Therapeutics, Inc. has a 12-month low of $0.44 and a 12-month high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.06). Research analysts expect that Century Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Wall Street Zen downgraded Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a research report on Thursday, July 2nd. Finally, Mizuho began coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Century Therapeutics presently has an average rating of “Hold” and an average target price of $4.75.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.